Inventor · disambiguated record
Thomas M. Estok
Also filed as: ESTOK THOMAS · ESTOK THOMAS M · ESTOK THOMAS MARK
6 granted patents·10 pending applications·97 citations·filing 1998–2023
83Inventor score
Files withESTOK THOMAS M5SCHERING CORP4DRACEN PHARMACEUTICALS INC3COTHERA BIOSCIENCE INC2LAWHON TRACY1
Top patents by PatentIndex Score
16 records- 0187US8247423B2Methods and compositions for the treatment of cancer, tumors, and tumor-related disordersESTOK THOMAS M·Filed 2008·Granted Aug 21, 2012·23 cites·24 claims
- 0273US6001845ACombination of phentolamine and apomorphine for the treatment of human sexual function and dysfunctionSCHERING CORP·Filed 1999·Granted Dec 14, 1999·44 cites·11 claims
- 0369US2024156824A1Treatment of cancer with tg02COTHERA BIOSCIENCE INC·Filed 2023·Application pending·0 cites
- 0462US6136818ACombination of phentolamine and apomorphine for the treatment of human sexual function and dysfunctionSCHERING CORP·Filed 1999·Granted Oct 24, 2000·17 cites·1 claims
- 0558US11865116B2Treatment of cancer with TG02COTHERA BIOSCIENCE INC·Filed 2017·Granted Jan 9, 2024·0 cites·8 claims
- 0657US6011043ACombination of phentolamine and apomorphine for the treatment of human sexual function and dysfunctionSCHERING CORP·Filed 1998·Granted Jan 4, 2000·13 cites·10 claims
- 0753US11173160B2Use of TG02 for treating gliomas in pediatric subjectsUNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION·Filed 2020·Granted Nov 16, 2021·0 cites·9 claims
- 0853US2012015919A1Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonistsESTOK THOMAS M·Filed 2008·Application pending·0 cites
- 0945US2023372294A1Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereofDRACEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1044US2010112039A1Methods of treating ovarian cancerSCHERING CORP·Filed 2007·Application pending·0 cites
- 1143US2011306572A1COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]ESTOK THOMAS M·Filed 2008·Application pending·0 cites
- 1243US2012016002A1Patient Selection and Therapeutic Methods Using Markers of Prostaglandin MetabolismLAWHON TRACY·Filed 2008·Application pending·0 cites
- 1342US2012052061A1Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitorsESTOK THOMAS M·Filed 2008·Application pending·0 cites
- 1441US2013084281A1Methods and compositions for the treatment of cancer, tumors, and tumor-related disordersESTOK THOMAS M·Filed 2012·Application pending·0 cites
- 1540US2022332676A1Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereofDRACEN PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1637US2022117938A1Combinaton therapy with a don prodrug and an immune checkpoint inhibitorDRACEN PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas M. Estok files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →